T1	Eq-Comparison 34 47	over 60 years
E1	Eq-Comparison:T1 Operator:T33 Value:T34 Temporal-Unit:T35
T2	Age 51 54	age
E2	Age:T2 Eq-Comparison:E1
T3	And 55 59	with
E3	And:T3 Arg:E2 Arg2:E4
T4	Condition 84 103	Parkinson's disease
E4	Condition:T4 Name:T36
T5	Eq-Comparison 131 134	2-3
E5	Eq-Comparison:T5 Value:T54 Operator:T55 Value2:T56
T9	Negation 158 161	Not
E9	Negation:T9 Negates:E10
T10	Condition 162 180	exposed to tobacco
E10	Condition:T10 Name:T38
T11	Temporal-Connection 181 187	during
E11	Temporal-Connection:T11 Arg:E10 Arg2:E7
A1	Temporal-Connection-Type-Value E11 during
T13	Negation 217 219	No
E13	Negation:T13 Negates:E15
T14	Eq-Comparison 220 227	history
E14	Eq-Comparison:T14 Temporal-Period:T40
T15	Condition 231 244	lung diseases
E15	Condition:T15 Name:T41 Temporality:E14
T16	Negation 250 252	No
E16	Negation:T16 Negates:E8
T18	Negation 283 285	No
E18	Negation:T18 Negates:E12
T19	Eq-Comparison 286 293	history
E19	Eq-Comparison:T19 Temporal-Period:T43
T20	Drug 318 326	nicotine
E20	Drug:T20 Name:T44
T21	Assertion 332 339	Able to
E21	Assertion:T21 Asserted:E22
A2	Assertion-Type-Value E21 hypothetical
T22	Drug 344 364	nicotine nasal spray
E22	Drug:T22 Name:T45
T23	Assertion 395 402	able to
E23	Assertion:T23 Asserted:E17
A3	Assertion-Type-Value E23 hypothetical
T24	Eq-Comparison 431 444	Under current
E24	Eq-Comparison:T24 Temporal-Period:T46
T25	Procedure 445 454	treatment
E25	Procedure:T25 Temporality:E24
T26	Drug 460 468	levodopa
E26	Drug:T26 Name:T47 Stability:T48
T27	Negation 491 494	Not
E27	Negation:T27 Negates:E34
T28	Eq-Comparison 495 514	currently receiving
E28	Eq-Comparison:T28 Temporal-Period:T49
T29	Drug 517 544	monoamine oxidase inhibitor
E29	Drug:T29 Name:T51
T30	Negation 579 585	Unable
E30	Negation:T30 Negates:E35
T31	Condition 627 643	adverse reaction
E31	Condition:T31 Name:T52
T32	Death 649 654	Death
E32	Death:T32 
T33	Eq-Operator 34 38	over
A4	Eq-Operator-Value T33 GT
T34	Eq-Value 39 41	60
T35	Eq-Temporal-Unit 42 47	years
A5	Eq-Temporal-Unit-Value T35 year
T36	Condition-Name 84 103	Parkinson's disease
T38	Condition-Name 162 180	exposed to tobacco
T40	Eq-Temporal-Period 220 227	history
A6	Eq-Temporal-Period-Value T40 past
T41	Condition-Name 231 244	lung diseases
T42	Observation-Name 253 263	laboratory
T43	Eq-Temporal-Period 286 293	history
A7	Eq-Temporal-Period-Value T43 past
T44	Drug-Name 318 326	nicotine
T45	Drug-Name 344 364	nicotine nasal spray
T46	Eq-Temporal-Period 431 444	Under current
A8	Eq-Temporal-Period-Value T46 present
T47	Drug-Name 460 468	levodopa
T48	Stability 474 480	stable
A9	Stability-Value T48 stable
T49	Eq-Temporal-Period 495 514	currently receiving
A10	Eq-Temporal-Period-Value T49 present
T51	Drug-Name 517 544	monoamine oxidase inhibitor
T52	Condition-Name 627 643	adverse reaction
T53	Coreference 119 130	the disease
E33	Coreference:T53 Refers-To:E4 Stage:E5
T54	Eq-Value 131 132	2
T55	Eq-Operator 132 133	-
A12	Eq-Operator-Value T55 BETWEEN
T56	Eq-Value 133 134	3
T6	Modifier 138 152	Hoehn and Yahr
E6	Modifier:T6 Modifies:E33
T7	Eq-Comparison 188 211	any stage of their life
E7	Eq-Comparison:T7 Temporal-Period:T8
T8	Eq-Temporal-Period 188 211	any stage of their life
A13	Eq-Temporal-Period-Value T8 anytime
A14	Observation-Type-Value T42 lab
T12	Observation 253 263	laboratory
E8	Observation:T12 Name:T42 Polarity:T17
T17	Polarity 264 277	abnormalities
A15	Polarity-Value T17 abnormal
T37	Condition 297 314	adverse reactions
E12	Condition:T37 Name:T39 Temporality:E19
T39	Condition-Name 297 314	adverse reactions
R1	Caused-By Arg1:E12 Arg2:E20	
T57	Location 383 394	Mexico City
A16	Location-Value T57 residence
T58	Study 414 425	evaluations
E17	Study:T58 
R2	Using Arg1:E25 Arg2:E26	
T50	Procedure 545 554	treatment
E34	Procedure:T50 Temporality:E28
R3	Using Arg1:E34 Arg2:E29	
T59	Encounter 598 607	follow-up
E35	Encounter:T59 
T60	Assertion 579 585	Unable
E36	Assertion:T60 Asserted:E30
A11	Assertion-Type-Value E36 hypothetical
T61	Drug 622 626	Drug
E37	Drug:T61 
R4	Caused-By Arg1:E31 Arg2:E37	
